Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13264513 | 0.87 | CYP3A4 (0.31) | CYP3A4TDP1 | |
| SCHEMBL17058591 | 0.82 | CYP3A4 (0.31) | CYP3A4TDP1 | |
| SCHEMBL19286240 | 0.81 | CYP3A4 (0.35) | CYP3A4TDP1 | |
| SCHEMBL12951432 | 0.78 | CYP3A4 (0.35) | CYP3A4TDP1 | |
| SCHEMBL16328150 | 0.75 | MEN1 (0.34) | MEN1MAPTCYP2C9KMT2ACYP3A4 | |
| SCHEMBL17058646 | 0.72 | CHRNA7 (0.33) | — | |
| SCHEMBL15344680 | 0.72 | ROCK2 (0.33) | — | |
| SCHEMBL19286305 | 0.70 | HTT (0.42) | MEN1MAPTKMT2ATDP1 | |
| SCHEMBL6544819 | 0.68 | CYP3A4 (0.39) | CYP3A4TDP1 | |
| SCHEMBL16327316 | 0.66 | CYP3A4 (0.31) | CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9744528-B2 | Metallorganocatalysis for asymmetric transformations | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160023198-A1 | Metallorganocatalysis For Asymmetric Transformations | Rutgars, The State University of New Jersey (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160023198-A1 | Metallorganocatalysis For Asymmetric Transformations | SOD1, AOC3, CBR1 | MEN1 3293/4885MAPT 3139/4885CYP2C9 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.